Wealth Enhancement Advisory Services LLC Has $86.14 Million Stake in Medtronic PLC $MDT

Wealth Enhancement Advisory Services LLC increased its stake in Medtronic PLC (NYSE:MDT) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 855,915 shares of the medical technology company’s stock after acquiring an additional 43,664 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Medtronic were worth $86,135,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the second quarter worth $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the third quarter valued at about $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the third quarter valued at about $29,000. Board of the Pension Protection Fund bought a new position in shares of Medtronic during the 4th quarter worth about $29,000. Finally, GoalVest Advisory LLC bought a new position in shares of Medtronic during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of research analyst reports. Mizuho raised Medtronic to a “strong-buy” rating in a research report on Wednesday, February 18th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, March 1st. CICC Research started coverage on Medtronic in a research report on Friday, January 30th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. cut their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Price Performance

MDT stock opened at $86.29 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The business has a 50-day simple moving average of $96.82 and a two-hundred day simple moving average of $96.72. The company has a market capitalization of $110.78 billion, a P/E ratio of 24.03, a price-to-earnings-growth ratio of 2.21 and a beta of 0.71. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the prior year, the business posted $1.38 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).